Author

M. J. F. Crupi

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Organism:human· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:host-pathogen & immune response· 2 Assay:proteomics· 2 Assay:bulk RNA-seq· 1 Research Focus:metabolism & bioenergetics· 1

Frequent Co-Authors

J. C. Bell· 2 shared A. Buchler· 1 shared A. Hagerman· 1 shared A. N. Rekab· 1 shared A. Pelin· 1 shared A. Surendran· 1 shared B. Austin· 1 shared B. D. Hyndman· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. C. Bell

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Loss of Tumour Suppressor TMEM127 Drives RET-mediated Transformation Through Disrupted Membrane Dynamics

T. J. Walker, E. Reyes-Alvarez, B. D. Hyndman, M. G. Sugiyama, L. C. B. Oliveira, A. N. Rekab, M. J. F. Crupi, R. Cabral-Dias, Q. Guo, P. L. M. Dahia, D. S. Richardson, C. N. Antonescu, L. M. Mulligan

This study shows that TMEM127 loss leads to RET receptor accumulation on the cell surface, promoting constitutive signaling and cell proliferation in PCC.

bioRxiv · Jun 28, 2023 · PreprintCancer Biology

More than a ligand: PD-L1 promotes oncolytic virus infection via a metabolic shift that inhibits the type I interferon pathway.

J. Hodgins, J. Abou-Hamad, A. Hagerman, E. Yakubovich, C. Tanese De Souza, M. Marotel, A. Buchler, S. Fadel, M. Park, C. Fong-McMaster, M. J. F. Crupi, J. C. Bell, M.-E. Harper, B. Rotstein, R. Auer, , M. Ardolino

PD-L1 promotes oncolytic virus infection by inhibiting the type I interferon pathway through a metabolic shift involving enhanced glycolysis and lactate production.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

Characterization of Critical Determinants of ACE2-RBD Interaction

E. E. F. Brown, R. Rezaei, T. Jamieson, J. Dave, N. T. Martin, R. Singaravelu, M. J. F. Crupi, S. Boulton, S. Tucker, J. Duong, J. Poutou, A. Pelin, H. Yasavoli-Sharahi, Z. Taha, R. Arulanandam, , T. Azad

This study identifies critical amino acid residues in SARS-CoV-2 RBD and ACE2 that influence binding affinity and neutralization by antibodies and inhibitors.

bioRxiv · Jan 29, 2021 · PreprintMicrobiology